Nanologica AB (SE:NICA)
:NICA
Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr189.37M
Enterprise Valuekr139.41M
Total Cash (Recent Filing)kr39.25M
Total Debt (Recent Filing)kr119.07M
Price to Earnings (P/E)2.1
Beta1.32
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding328,769,840
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr83.10M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth of ~50.7% signals strengthening commercial traction in pharmaceutical customers and growing product adoption. Over 2-6 months this supports scale economies, expands reference use cases for the platform, and increases the odds of future margin recovery once fixed costs are absorbed.
Proprietary Silica TechnologyA focused silica-based chromatographic platform is a durable structural advantage in pharma purification where material performance matters. Specialized media create technical barriers, encourage long-term customer validation cycles, and support recurring consumable sales and services across process development and manufacturing.
Positive Equity And Asset BaseA larger asset base and reported positive equity provide a firmer capital foundation than for many peers. Over the medium term this supports continued R&D and scale-up investment, gives creditors and partners greater confidence, and increases optionality for financing or commercial expansion if cash needs are managed.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow (~-26.9M and -27.9M TTM) indicates the business cannot self-fund growth and operations. Over months this raises dilution and refinancing risk, constrains R&D or capacity investments, and forces management to prioritize cash preservation over strategic initiatives.
Operating Losses & Margin WeaknessDeeply negative gross and operating profits mean unit economics and operating leverage are not yet sustainable. Even with top-line growth, continued operating losses suggest the company must materially improve margins or cut costs to deliver durable profitability; net income appears influenced by non-operating items.
Rising LeverageMaterial increase in leverage (debt/equity ~1.22) while the company remains loss-making reduces financial flexibility. Over 2-6 months higher interest and covenant risk can limit strategic options, increase refinancing cost, and amplify downside if commercial improvement stalls or cash burn persists.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr189.37M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Aug 27, 2026 which is in 85 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on May 20, 2026. The company reported kr0.719 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.719.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of kr0.719 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 32.383%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―